Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANDA Submissions Continue Yo-Yo Pattern, Unlike Approvals

Executive Summary

After spike in March, generic drug application submissions drop 62% in April, while approval volume remains at monthly average.

You may also be interested in...



ANDA Approvals Break Record, May Set New Normal

FDA's June approval total is highest of GDUFA era, but does it signal a new elevated productivity level for the generics program?

ANDA Approvals Break Record, May Set New Normal

FDA's June approval total is highest of GDUFA era, but does it signal a new elevated productivity level for the generics program?

FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit

Prioritizing ANDAs entering markets with fewer than three approved generics not expected to become a major advantage until first-cycle clearances increase.

Related Content

Topics

UsernamePublicRestriction

Register

PS120598

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel